SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third-quarter report and managements upbeat 2027 outlook have driven CLFs sharp rally, with bullish traders focused on improved steel pricing and possible short covering. Others question whether the outlook can overcome the companys debt and execution concerns, and some view the move as a sell-the-news bounce.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy pressure amid IPO lockup-related selling concerns and a broader AI and semiconductor pullback, with traders also questioning the companys valuation, growth, and ability to scale. Bears expect further downside as more shares become eligible for sale, while bulls view the selloff as excessive and are averaging in.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy after a sharp selloff fueled hopes of a rebound, but traders debated whether the upgrade could overcome ongoing financing concerns, especially as the rally faded. Bulls point to AI demand, customer commitments and Nvidias support, while bears remain focused on CoreWeaves heavy debt burden and borrowing costs.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDAs early expansion of ANKTIVA plus BCG to papillary-only BCG-unresponsive bladder cancer, alongside long-term data showing durable responses, is driving discussion about a larger patient market and future sales. Traders are puzzled by the share-price decline despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling or options-related pressure.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under pressure after a prolonged decline, with traders frequently blaming insider share sales and frustration that management has not announced a fresh buyback. Some see the selloff as a buying opportunity given the companys growth and cash position, while others warn the stock may keep falling and question its valuation and management.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as traders focus on financing costs, debt concerns and doubts about the sectors business models, with CoreWeaves credit worries adding to contagion fears. The community is split on whether sharp rebounds are durable or bull traps: bulls point to Nebiuss comparatively stronger balance sheet and long-term compute demand, while bears question the capital intensity and path to profitability.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Sharp post-IPO selling and volatile trading dominate the discussion, with traders pointing to lockup-related supply, bearish analyst coverage, and weakness across nuclear stocks as possible pressures. Bulls are treating the pullback as an opportunity, citing Amazons backing and X-energys potential role in meeting future data-center power demand, while others stress that reactor commercialization remains years away.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on the FDA-cleared expansion of Alpha Taus REGAIN trial for recurrent glioblastoma and anticipated clinical data at the SNO meeting. Traders are bullish on early tumor-control findings and the broader pipeline, though some note the evidence comes from a small initial cohort.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almontys investor-day webcast is drawing criticism, with traders disappointed by CEO Lewis Blacks presentation and questioning whether it offered meaningful new information. Some speculate that management appeared evasive, but those concerns are unverified; broader weakness in critical-minerals stocks is also part of the discussion.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons advance is drawing attention after Morgan Stanley named it a top pick, citing AWS growth, AI opportunities and warehouse automation as potential catalysts. Traders are broadly bullish on the move, though some remain cautious about heavy AI spending and whether the shares can sustain gains ahead of earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...

Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?

Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 9, 2026 Insiders may stand to...

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN...

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of...

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction...

Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today

GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.read more...

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether Cyclerion...

Promising Medical Stocks To Consider - April 1st

Eli Lilly and Company, Cyclerion Therapeutics, Apellis Pharmaceuticals, UnitedHealth Group, Novo Nordisk A/S, Boston Scientific, and Johnson & Johnson are the seven Medical stocks to watch today...

Best Pharmaceutical Stocks To Follow Now - April 1st

Eli Lilly and Company, Cyclerion Therapeutics, Apellis Pharmaceuticals, Novo Nordisk A/S, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics shares are trading sharply higher Wednesday morning after it announced a merger agreement with Korsana Biosciences.read more...

Korsana Biosciences, Inc. is a biopharmaceutical company, which engages in discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its portfolio includes the KRSA-028 pipeline. The company was founded in 2024 and is headquartered in Waltham, MA.

Korsana Biosciences Inc.

CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction.</li><li>The company added that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029.</li><li>Korsana expects the financing round to close immediately prior to the proposed merger.</li></ul>Cyclerion Therapeutics Inc. (CYCN) shares more than tripled in Wednesday’s opening trade, rallying by more than 274% after the company announced a deal with Korsana Biosciences Inc.Cyclerion stated that it has entered into a definitive merger agreement for an all-stock transaction. The merged entity will operate under the name Korsana Biosciences Inc., and trade on the Nasdaq under the ticker symbol ‘KRSA’.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CYCN">Cyclerion Therapeutics</a> trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Korsana Secures $380M In Commitments To Support Merger</h2>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction. The investment is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, and Wellington Management, among others.The company expects the financing round to close immediately prior to the proposed merger.Korsana stated that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029, providing it with runway through key clinical milestones.“With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Korsana CEO Jonathan Violin.<h2 class="st-heading-2">What Does Korsana Do?</h2>Korsana is a Waltham, Massachusetts-based company that is engaged in the development of therapeutics to treat neurodegenerative diseases.Its lead program is KRSA-028, a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics.KRSA-028 is designed to enhance amyloid plaque clearance, lower amyloid-related imaging abnormalities (ARIA) and hematologic risks, and improve convenience through low-volume subcutaneous delivery.<a href="https://stocktwits.com/symbol/CYCN">CYCN stock</a> is up 357% year-to-date and 128% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months, while the Fidelity Nasdaq Composite Index ETF (ONEQ) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ipm-bcg-hubc-stocks-top-premarket-gainers-april-1-2026/cZ7H1jsRInn">IPM, BCG, HUBC Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Cyclerion stated that it has entered into a definitive merger agreement with Korsana Therapeutics in an all-stock transaction.

Cyclerion Therapeutics Inc

Fidelity Nasdaq Composite Index ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$32.82
Prev Close	$32.38
Open	$32.60
Dividend Yield	0.00%
50-Day Moving Average	$30.26
Beta	0.29
Avg. Volume	67,184.85
PE Ratio	-2.75

52-Week High	$59.36
52-Week Low	$7.19
Market Capitalization	$1.47B
EPS (Annual)	-$7.76
Price to Book	3.87
Revenue Per Employee	$2.07M

Feed

News

Sentiment

Fundamentals

Info

CYCN Fundamentals